Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial

American Journal of Ophthalmology

Volumn 177, Issue , 2017, Pages 150-158

  Constable, Ian J ^a,b,d   Lai, Chooi May ^a,b   Magno, Aaron L ^a   French, Martyn A ^c,e   Barone, Samuel B ^f   Schwartz, Steven D ^g   Blumenkranz, Mark S ^h   Degli Esposti, Mariapia A ^a,b   Rakoczy, Elizabeth P ^a,b  

^a LIONS EYE INSTITUTE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f Adverum Biotechnologies Inc   (United States)

^g JULES STEIN EYE INSTITUTE   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; GAMMA GLUTAMYLTRANSFERASE; RANIBIZUMAB; VASCULOTROPIN RECEPTOR 1; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADENO ASSOCIATED VIRUS; AGE RELATED MACULAR DEGENERATION; AGED; ALLERGY; ALZHEIMER DISEASE; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONFUSION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EYE DISEASE; FOLLOW UP; GENE THERAPY; HEART DISEASE; HUMAN; HYPERTENSION; INFESTATION; INTOXICATION; LONG TERM CARE; MALAISE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEUROLOGIC DISEASE; OSTEOPOROSIS; PARS PLANA VITRECTOMY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINUS BRADYCARDIA; SUBRETINAL DRUG ADMINISTRATION; VASCULAR DISEASE; VERTEBRAL CANAL STENOSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VISUAL ACUITY; WET MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; FEMALE; INJECTION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PROCEDURES; RETINA; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VITRECTOMY;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENETIC THERAPY; HUMANS; INJECTIONS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; RECEPTORS, INTERLEUKIN-1; RETINA; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; WET MACULAR DEGENERATION;

EID: 85015888556     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2017.02.018     Document Type: Article

References (37)

1. 1 Wong, T.Y., Chakravarthy, U., Klein, R., et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115:1 (2008), 116–126.
2. 2 Friedman, D.S., O'Colmain, B.J., Munoz, B., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:4 (2004), 564–572.
3. 3 Nowak, J.Z., Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 58:3 (2006), 353–363.
4. 4 Kaiser, P.K., Brown, D.M., Zhang, K., et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:6 (2007), 850–857.
5. 5 Regillo, C.D., Brown, D.M., Abraham, P., et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:2 (2008), 239–248.
6. 6 Ueta, T., Noda, Y., Toyama, T., Yamaguchi, T., Amano, S., Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. Ophthalmology, 121(11), 2014 2193–2203.e2191-2197.
7. 7 Lim, L.S., Cheung, C.M., Mitchell, P., Wong, T.Y., Emerging evidence concerning systemic safety of anti-VEGF agents–should ophthalmologists be concerned?. Am J Ophthalmol 152:3 (2011), 329–331.
8. 8 Moja, L., Lucenteforte, E., Kwag, K.H., et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev, 9, 2014, CD011230.
9. 9 Scott, L.J., Chakravarthy, U., Reeves, B.C., Rogers, C.A., Systemic safety of anti-VEGF drugs: a commentary. Expert Opin Drug Saf 14:3 (2015), 379–388.
10. 10 Thulliez, M., Angoulvant, D., Le Lez, M.L., et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132:11 (2014), 1317–1326.
11. 11 Tolentino, M., Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56:2 (2011), 95–113.
12. 12 Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Romano, M.R., Costagliola, C., Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opin Drug Saf 13:6 (2014), 785–802.
13. 13 Curtis, L.H., Hammill, B.G., Qualls, L.G., et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol 153:6 (2012), 1116–1124.e1111.
14. 14 Lad, E.M., Hammill, B.G., Qualls, L.G., Wang, F., Cousins, S.W., Curtis, L.H., Anti-VEGF treatment patterns for neovascular age-related macular degeneration among Medicare beneficiaries. Am J Ophthalmol 158:3 (2014), 537–543.e532.
15. 15 Brechner, R.J., Rosenfeld, P.J., Babish, J.D., Caplan, S., Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file. Am J Ophthalmol 151:5 (2011), 887–895.e881.
16. 16 Day, S., Acquah, K., Lee, P.P., Mruthyunjaya, P., Sloan, F.A., Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol 152:6 (2011), 1014–1020.
17. 17 Qualls, L.G., Hammill, B.G., Wang, F., et al. Costs of newly diagnosed neovascular age-related macular degeneration among Medicare beneficiaries, 2004-2008. Retina 33:4 (2013), 854–861.
18. 18 Kendall, R.L., Thomas, K.A., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90:22 (1993), 10705–10709.
19. 19 Asokan, A., Schaffer, D.V., Samulski, R.J., The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20:4 (2012), 699–708.
20. 20 Maclachlan, T.K., Lukason, M., Collins, M., et al. Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol Ther 19:2 (2011), 326–334.
21. 21 Lukason, M., DuFresne, E., Rubin, H., et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 19:2 (2011), 260–265.
22. 22 Lebherz, C., Maguire, A.M., Auricchio, A., et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 54:4 (2005), 1141–1149.
23. 23 Lebherz, C., Maguire, A., Tang, W., Bennett, J., Wilson, J.M., Novel AAV serotypes for improved ocular gene transfer. J Gene Med 10:4 (2008), 375–382.
24. 24 Lai, Y.K., Shen, W.Y., Brankov, M., Lai, C.M., Constable, I.J., Rakoczy, P.E., Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 9:12 (2002), 804–813.
25. 25 Lai, C.M., Shen, W.Y., Brankov, M., et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12:4 (2005), 659–668.
26. 26 Lai, C.M., Estcourt, M.J., Wikstrom, M., et al. rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci 50:9 (2009), 4279–4287.
27. 27 Lai, C.M., Estcourt, M.J., Himbeck, R.P., et al. Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther 19:10 (2012), 999–1009.
28. 28 Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:14 (2006), 1419–1431.
29. 29 Brown, D.M., Michels, M., Kaiser, P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116:1 (2009), 57–65.e55.
30. 30 Rakoczy, E.P., Lai, C.M., Magno, A.L., et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 386:10011 (2015), 2395–2403.
31. 31 Bhisitkul, R.B., Mendes, T.S., Rofagha, S., et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 159:5 (2015), 915–924.e912.
32. 32 Chakravarthy, U., Harding, S.P., Rogers, C.A., et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:9900 (2013), 1258–1267.
33. 33 Martin, D.F., Maguire, M.G., Fine, S.L., et al. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:7 (2012), 1388–1398.
34. 34 Silva, R., Axer-Siegel, R., Eldem, B., et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 120:1 (2013), 130–139.
35. 35 Singer, M.A., Awh, C.C., Sadda, S., et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119:6 (2012), 1175–1183.
36. 36 Gupta, O.P., Shienbaum, G., Patel, A.H., Fecarotta, C., Kaiser, R.S., Regillo, C.D., A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117:11 (2010), 2134–2140.
37. 37 Rayess, N., Houston, S.K. 3rd, Gupta, O.P., Ho, A.C., Regillo, C.D., Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 159:1 (2015), 3–8.e1.